ARCHIVES

Fund Squeeze Results In Percentage reductions for Renewed Program Project, Center Core Grants

This article is from The Cancer Letter archive.

Vol. 03 No. 14 | April 8, 1977

Download PDF Visit The Full Archive

Related Articles

BRAF Inhibitor Shrank Tumors In Phase II Genentech Study

November 26, 2010

Guest Editorial: Learning from the Power Morcellation Fiasco: Government Must Do More to Regulate Devices

September 12, 2014

Velcade Addition Can Improve Graft-Versus-Host Outcomes

December 27, 2013

Neratinib Graduates from I-SPY Phase II Adaptive Trial Regimen

April 25, 2014

Two Phase II Ibrutinib Studies Presented to EHA Demonstrate Efficacy as a Monotherapy

July 26, 2013

Guest Editorial: The Supreme Court Decision on the ACA and What It Can Mean to Oncology

June 29, 2012